Institutional Investor’s Pro-Wavetrue Inc (NASDAQ:PRTK) Sentiment In 2018 Q1

July 13, 2018 - By Richard Doty

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Logo

Sentiment for Wavetrue Inc (NASDAQ:PRTK)

Wavetrue Inc (NASDAQ:PRTK) institutional sentiment increased to 2.31 in 2018 Q1. Its up 1.40, from 0.91 in 2017Q4. The ratio improved, as 67 investment managers started new or increased positions, while 29 sold and reduced stakes in Wavetrue Inc. The investment managers in our partner’s database now own: 20.55 million shares, up from 19.34 million shares in 2017Q4. Also, the number of investment managers holding Wavetrue Inc in their top 10 positions increased from 1 to 2 for an increase of 1. Sold All: 16 Reduced: 13 Increased: 45 New Position: 22.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. The company has market cap of $339.66 million. The Company’s lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections , community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. It currently has negative earnings. The firm has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP.

The stock increased 1.42% or $0.15 during the last trading session, reaching $10.75. About 266,559 shares traded. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has declined 50.36% since July 13, 2017 and is downtrending. It has underperformed by 62.93% the S&P500.

Analysts await Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report earnings on August, 1. They expect $-0.96 EPS, down 50.00 % or $0.32 from last year’s $-0.64 per share. After $-0.91 actual EPS reported by Paratek Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 5.49 % negative EPS growth.

Abingworth Llp holds 8.41% of its portfolio in Paratek Pharmaceuticals, Inc. for 1.04 million shares. Roumell Asset Management Llc owns 197,347 shares or 5.65% of their US portfolio. Moreover, Trellus Management Company Llc has 2.12% invested in the company for 89,700 shares. The New York-based Broadfin Capital Llc has invested 0.97% in the stock. Highland Capital Management Lp, a Texas-based fund reported 959,278 shares.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ratings Coverage

Ratings analysis reveals 100% of Paratek Pharmaceuticals’s analysts are positive. Out of 3 Wall Street analysts rating Paratek Pharmaceuticals, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $50.0 while the high is $55. The stock’s average target of $47 is 337.21% above today’s ($10.75) share price. PRTK was included in 3 notes of analysts from March 1, 2018. The firm has “Outperform” rating given on Friday, March 2 by Raymond James. The firm earned “Buy” rating on Thursday, March 1 by Cantor Fitzgerald. The firm has “Buy” rating by H.C. Wainwright given on Friday, March 2.

More recent Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) news were published by: which released: “Paratek Announces FDA Advisory Committee Date for Omadacycline” on June 20, 2018. Also published the news titled: “Paratek Pharmaceuticals: Three PDUFA Dates, One Option Trade” on July 08, 2018.‘s news article titled: “Paratek: Key FDA Dates Are Approaching” with publication date: July 13, 2018 was also an interesting one.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.